Ascendia

 

  MARKET NEWS

Jupiter Neurosciences Highlights Critical Advancement of JOTROL Over Traditional Resveratrol With Breakthrough Bioavailability & CNS-Targeted Science
Roquette Unveils POLYOX ES Packaging to Advance Excipient Stability & Sustainability
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas Wearable Injector Technology for Biologic Drugs
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
Leriglitazone Marketing Authorization Application Submitted for Treatment of Cerebral Adrenoleukodystrophy Has Been Validated by EMA
Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Arch Biopartners Announces Start of Patient Recruitment in Phase 2 Trial Targeting Drug-Toxin-Related Acute Kidney Injury
etherna Achieves Major Milestones in its Bio-Reducible LNP Platform
Nemera Expands Production Capacity in Szczecin to Strengthen Leadership in GLP-1 Drug Market

  EXPERT CONTENT & RESOURCES

EXECUTIVE INTERVIEW - Plus Therapeutics: Advancing Targeted Radiotherapeutics for Rare & Difficult-to-Treat Cancers

EXECUTIVE INTERVIEW - Plus Therapeutics: Advancing Targeted Radiotherapeutics for Rare & Difficult-to-Treat Cancers

Dr. Marc Hedrick, CEO of Plus Therapeutics, discusses the company’s targeted radiotherapeutic platform for central nervous system and solid tumor cancers and why internal radiation therapy offers patients a more advanced drug delivery solution compared to traditional external radiation therapy.

Exploring New Potential Through 505(b)(2)

Exploring New Potential Through 505(b)(2)

When filing for a drug product approval via the 505(b)(2) regulatory pathway rather than a traditional development pathway, companies are afforded several advantages.

Understanding the Foundation of LNP Formulation Success

Understanding the Foundation of LNP Formulation Success

Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….

  FEATURED EDITORIAL

  COMPANY PROFILE

Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics, small molecules, and RNA to meet the goals of patient-centric therapies, improved medicine and better healthcare economics. Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support through the Celanese Development & Feasibility Lab. Our objective is to help our customers reduce R&D time and improve the likelihood of successful drug commercialization. Click here for more.

  WHITEPAPERS & WEBINARS

vytal webinar

WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future

In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - OXYCAPT™: Multilayer Plastic Vial: An Optimal Primary Container for Drug Products Transported With Dry Ice

WHITEPAPER - OXYCAPT™: Multilayer Plastic Vial: An Optimal Primary Container for Drug Products Transported With Dry Ice

Providing Ideal Protection for Invaluable Drug Products, Including Cell and Gene Therapy Products

Product Introduction of OXYCAPT™

OXYCAPT™ is a multilayer plastic vial and syringe, consisting of three layers made from two types of resins.  The drug contact layer and …

WHITEPAPER - Container Selection for a Highly Sensitive Drug Product: A Success Story

WHITEPAPER - Container Selection for a Highly Sensitive Drug Product: A Success Story

Our client, a leading pharmaceutical company, came to us for a solution to a very specific problem. They needed a staked needle prefilled syringe (PFS) in a disposable auto-injector for their high-concentration monoclonal antibody product. These products are among the …

WHITEPAPER: Partnering With Gattefossé to Tackle Veterinary Medicine Challenges

WHITEPAPER: Partnering With Gattefossé to Tackle Veterinary Medicine Challenges

Veterinary medicines face unique challenges due to species diversity, physiology, and dosing needs. Animals can’t be instructed to take medicine, so palatability, safety, and bioavailability are key.

Gattefossé focuses on customers, veterinarians, pet owners, and animals themselves to help them …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 30 – Drug Delivery
August – 6 – Injection Devices